Background. Salmonella Typhi is the major cause of enteric fever in lower-income countries. New conjugate vaccines show promise as public health interventions, but there are no efficacy data available from endemic areas.
Salmonella enterica subspecies enterica serovar Typhi (S. Typhi) is a major cause of invasive bacterial infection, particularly in children in low-and middle-income countries. Vaccines available for prevention of typhoid fever include Vi polysaccharide vaccine (Vi-PS) and live attenuated oral vaccines. Both types of vaccine induce protection of limited duration, are not licensed for administration in infants and young children (aged <2 years for Vi-PS and <6 years for live oral vaccines), and have not been widely implemented as routine public health interventions [1, 2] .
More recently, new Vi polysaccharide protein-conjugate vaccines have been developed for widespread use and show greater promise as routine public health interventions [3, 4] . Two conjugate vaccines with a tetanus toxoid carrier protein are licensed in India [3, 4] , one of which has been approved by the World Health Organization (WHO) for prequalification (Typbar TCV; Bharat Biotech International) [4] . Unlike plain polysaccharide vaccines, conjugate vaccines induce robust immune responses in young children [3] [4] [5] , and the technology has been used effectively to produce vaccines that prevent other bacterial infections such as Haemophilus influenzae type b, meningococcal, and pneumococcal disease [6] [7] [8] [9] [10] . However, there are no field efficacy estimates for the Vi polysaccharidetetanus toxoid conjugate vaccine (Vi-TT), and limited data on immunogenicity and the duration of protection [4, 11, 12] .
We provide an independent report on the seroefficacy and protective antibody levels from a phase III study of Vi-TT. Antibody concentrations generally peak 4-6 weeks after vaccination or after infection, decay sharply thereafter, and then plateau [13] . However, if a subsequent infection occurs, antibody levels will increase. Increases in antibody levels when a decline is expected, or sharp declines when antibody levels are expected to have plateaued, provide serological evidence of infection, which we used to assess the comparative protection afforded by these vaccines.
Typhoid conjugate vaccines were recently recommended by the WHO Strategic Advisory Group of Experts, and approved for financing by the Global Alliance for Vaccines and Immunisation. In the absence of any field efficacy studies with clinical end points for Typbar TCV, these results provide the only available evidence of the efficacy of this vaccine in an endemic field setting and are therefore important for the comprehensive review of the benefits of typhoid conjugate vaccines by global policy makers.
METHODS
Immunogenicity and demographic data were provided by Bharat Biotech International from their phase III, multicenter randomized controlled trial (RCT) that evaluated the immunogenicity and safety of Vi-TT versus Vi-PS in healthy subjects. Data from the primary phase of the study have been published elsewhere [4] . Briefly, participants aged 2-45 years were randomized to receive Vi-TT or Vi-PS. In an open-label arm participants aged 6-23 months received Vi-TT with no comparator vaccine group (Vi-TT open-label group).
Vaccines
The vaccines used in the study were Vi-TT (Typbar TCV; Bharat Biotech International) and Vi-PS (Typbar; Bharat Biotech International) (both 25 μg/0.5 mL, administered intramuscularly).
Laboratory Assays
Serum anti-Vi immunoglobulin G (IgG) antibody levels were tested using the commercially available VaccZyme enzymelinked immunosorbent assay kit (The Binding Site), per the manufacturer's instructions. The lower limit of assay quantification was 7.4 ELISA units (EU)/mL.
Statistical Analyses
Antibody results were log 10 -transformed and values below the lower limit of quantification of the assays were replaced with values of half the lower limit. To estimate comparative protection in the 2-year period after a single dose of vaccine, we used antibody levels at days 42, 540, and 720 to classify participants as having a presumed typhoid infection (symptomatic or asymptomatic) or not using gaussian finite mixture models. Mixture models are probabilistic models, that assume data are generated from a fixed number of underlying distributions and can be used to detect subpopulations within the data. The rate of decay of log-transformed antibody levels was calculated for each time period (days 42-540 and 540-720), and gaussian mixture models were fitted separately to the antibody decay rates for each time period.
Antibody titers at time points some distance removed from the original vaccination are a combination of residual circulating vaccine-induced antibody and antibody generated in response to exposure to antigens in the intervening period. In the absence of other exposures, vaccine-induced antibody from conjugate vaccines decays rapidly in the first year after vaccination and then less rapidly in the second year [13, 14] . We classified participants as having presumed typhoid infection if their antibody kinetics did not follow this pattern, and they were thus classified by mixture models as coming from a different subpopulation.
The proportion of infected persons in each group (seroincidence) was compared using relative risk (RR) and vaccine seroefficacy (VSE), computed as follows:
where RR C/P is the RR of infection from the data (Vi-TT vs Vi-PS); and VE P/0 is the estimate of vaccine efficacy (Vi-PS vs no Vi vaccine) from the published literature. Only participants with data at all 3 postvaccination time points were included in the analysis. Those with missing data at follow-up time points were compared with those with no missing data to determine whether this subset of participants was representative of the total randomized cohort in terms of age, sex, and initial antibody response to vaccination.
The relationship between log-Vi IgG at day 42 after vaccination and seroincidence of typhoid infection was examined using logistic regression models. All analyses were conducted using R software, version 3.3.2. Mixture models were fit using the mixtools software package [15] .
RESULTS

Baseline Characteristics of Participants Included in the Analysis
Antibody data at days 540 and 720 were available for 387 of 944 participants (41%). Of participants in the Vi-TT (RCT) group, 47% had full data, as did 42% of participants in the Vi-PS group. In comparison, the children in the younger open-label cohort had less data; only 34% with full data were included in the analysis (Table 1) .
In those receiving Vi-TT in the randomized trial, participants with full data available were older than those with missing data (median age, 10 vs 8 years; P = .01) and had lower antibody titers at day 42 (geometric mean, 1093 [95% confidence interval (CI), 931-1282] vs 1497 [1274-1760]; P = .007) ( Table 1 ). For the other 2 groups, there were no significant differences in age, sex, or antibody responses between those with missing data and those with full data (Table 1) .
RR of Infection Using a Serological Definition of Typhoid
The results of fitting mixture models to classify participants are shown in Figure 1 . Mixture models fit to antibody decay rates during the first time period (days 42-540) classified 13 participants as infected. All 13 participants had antibody levels that increased during this period ( Figure 1D ), consistent with exposure or infection, in contrast to those classified as presumed uninfected, whose antibody levels decayed ( Figure 1A ).
Mixture models fitted to antibody differences in the second time period (days 540-720) denoted 2 sets of participants with different antibody kinetics. The first group had antibody levels that increased during this 6-month period, consistent with exposure or infection during the intervening gap ( Figure 1B) , and the second group had antibody levels that decayed steeply during this period ( Figure 1C ), in contrast to the general population for whom antibody decay rates had flattened out by this time ( Figure 1A ). It is possible that some persons do have antibody that decays steeply during the entire 2-year period after an initial high postvaccination antibody concentration, we only included participants in this group if the rate of decay in the second period was greater than the rate in the first, because this is the opposite of what is seen in the uninfected group. These participants are therefore indicative of persons who have had exposure or infection not long before the day 540 time point, and as such their antibody levels are relatively high at day 540 and decaying rapidly. Some persons were classified as infected according to >1 method, because these definitions are not mutually exclusive.
Overall, 81 of 387 participants (21%) were classified using mixture models as having presumed typhoid infection at some point during the 2-year postvaccination period (Table 2) , and 34 of these received Vi-TT, resulting in an estimated seroincidence of infection of 13.2% after Vi-TT vaccination. The seroincidence in the Vi-PS group was 36%.
The risk of serologically defined typhoid infection was lower in participants randomized to Vi-TT than those receiving Vi-PS (21 of 155 [13.5%] vs 47 of 129 [36.4%], respectively; RR, 0.372; 95% CI, .235-.588; P < .001) ( Table 2 ). Similar RRs were seen when analyses were restricting to those aged 2-15 years, although with slightly wider CIs (RR, 0.424; 95% CI, .231-.778; P = .04). There was no significant difference in serologically defined typhoid infection rates between those receiving Vi-TT in the RCT (aged 2-45 years) and those receiving it in the open-label study (aged 6-23 months) (RR, 0.932; 95% CI, .489-1.776; P = .83) ( Table 2 ). In their systematic review, Anwar et al [12] report the 2-year efficacy of Vi polysaccharide vaccines as an RR of 0.41(95% CI, .31-.55) and vaccine efficacy of 59% (45%-69%). Based on these estimates, the vaccine seroefficacy of Vi-TT was 85% (95% CI, 80%-88%).
There was a strong relationship between seroincidence and anti-Vi IgG levels in logistic regression (odds ratio, 0.327; 95% CI, .206-.518). The probability of serologically defined infection calculated from the logistic model was 19% when anti-Vi IgG at day 42 was 1000 EU/mL (95% CI, 15%-23%) (Figure 2) .
DISCUSSION
In the absence of large field studies with suitable clinical end points we estimated vaccine efficacy using a serological definition of typhoid infection, and for the first time we show that instances of presumed typhoid infection in an endemic setting occur significantly less often with Vi-TT than with Vi-PS. The relative protection afforded by Vi-TT was the same when estimated in the full RCT cohort with participants aged 2-45 years and when restricted to children aged 2-15 years. In the open-label trial enrolling children aged 6-23 months, seroincidence after Vi-TT vaccination was the same as in those aged 2-45 years receiving this vaccine in the RCT. This may suggest a similar impact of vaccination in infants and toddlers as in older age groups. However, there was no control group for the younger children, so differential exposure rates in different age groups may also have influenced these comparisons. These findings are especially important because WHO has recently recommended the use of Vi-conjugate vaccine programs as a public health policy to control enteric fever.
A serological definition of infection is a simple method that can be used to compare groups in randomized trials. Infections defined using these methods are likely to include both clinical and subclinical infections; thus, the seroincidence of 13.2% estimated for those receiving the conjugate vaccine may be higher than the prevalence of clinical disease end points detected in field studies. However, subclinical infections associated with gastrointestinal shedding probably contribute to disease transmission, so vaccine efficacy against this end point is important in developing herd immunity [16] . Estimates of seroincidence derived using probabilistic methods are affected by misclassification, which can result in either over-or underestimation of the true rate of infection. A rise in antibody levels is probably due to exposure to S. Typhi bacteria but could also be due to cross-reactive epitopes expressed on other organisms or Vi polysaccharide capsules on the surface of unrelated bacteria, such as some strains of Citrobacter [17] . Alternatively, persistence of vaccine antigen might occur in some individuals and cause a rise in antibody that continues beyond the 6-week postvaccination time point in some individuals, but this would not account for rises after the later time points in this study. In contrast, an infected individual may generate a limited antibody response that decays by the time of the next blood sample, and such individuals will thus be misclassified as uninfected. Caution needs to be applied when interpreting the incidence of infection from serological data alone. One benefit of randomization in clinical trials is that the effect of misclassification will be balanced between groups and therefore add only random "noise" to comparisons, rather than inducing bias.
Using our serological definition of infection and the estimated vaccine efficacy for Vi-PS from a Cochrane review, we estimate the 2-year vaccine efficacy of Vi-TT to be 85% (95% CI, 80%−88%) after a single dose. This is similar to the only other robust field estimate of vaccine efficacy for a Vi-conjugate vaccine, which comes from a randomized trial in Vietnam [5] . The Vi-conjugate vaccine in that study contained recombinant Pseudomonas aeruginosa exotoxin A as the carrier protein.
The study administered 2 doses to children aged 2-5 years and observed a vaccine efficacy of 91% (79%-97%) [5] . Vaccine efficacy for Vi-TT has also been estimated in a challenge study in typhoid-naive adults in Oxford, where the vaccine efficacy was 55% (27%-72%) against symptomatic or asymptomatic infection during 14 days of follow-up [18] .
This finding is important, because this is the first attempt to estimate the efficacy of a Vi-TT vaccine from field data and it potentially provides strong support for the use of this vaccine in the programmatic control of enteric fever. However, large field efficacy trials such as those being conducted by the TyVAC consortium are needed to confirm or refine this estimate [19] .
In logistic regression models of seroincidence, there was a highly significant relationship between higher antibody levels measured 6 weeks after vaccination and protection against infection during the 2-year postvaccination period; however, no threshold antibody level provided complete protection. Even at antibody levels of 1000 EU/mL at day 42 after vaccination, there was still a 19% chance of serologically defined typhoid infection, similar to findings seen in Oxford typhoid challenge studies, in which a 25% chance of infection corresponded with an anti-Vi IgG concentration of 1000 EU/mL at the time of challenge [18] .
Defining a serological correlate of protection is desirable for vaccine development and can simplify the testing of new vaccines by comparing the number of vaccinees in immunogenicity studies with an immune response higher than a threshold level rather than conducting large field studies with rare clinical end points [20] . Correlates of protection for typhoid vaccines have been suggested previously based on different assays [21] ; however, the methods used to calculate such thresholds necessarily assume that such a threshold does exist, that is, that there is a level of Vi IgG antibody at which the probability of infection drops in a step function from a high to a very low probability of infection. Our findings confirm those seen in typhoid challenge studies showing that whereas higher anti-Vi IgG levels are associated with greater protection against typhoid infection, there is no threshold level where the probability of infection becomes negligible within the range of antibody levels induced by vaccination in this study. Even at the highest antibody level of 1500 EU/mL the 2-year probability of infection is still 10%.
Conjugate vaccines against H. influenzae type b, pneumococcus and meningococcus are thought to confer direct protection by both preventing acquisition of the organism on the upper airway mucosa and facilitating killing of organisms invading through the mucosa to the blood by means of bactericidal activity or opsonophagocytosis. In the context of invasive Salmonella infection, it is not clear how antibody-mediated protection operates and whether similar processes are involved, because the pathogens of enteric fever occupy an intracellular niche, at least during part of the infection process, and are therefore presumed to be inaccessible to antibody. It may be that anti-Vi antibody induced by the vaccine reduces or even blocks organisms invading through the mucosa or limits multiplication and spread between cells after invasion. A limitation of our study was that not all participants were followed up at all time points in this study, and thus many participants were excluded from the analysis. More data were available for the randomized trial than the open-label arm. Those receiving Vi-TT in the randomized trial who were included in the analysis were a slightly older cohort with lower antibody responses than those with missing data. A cohort with lower antibody responses would presumably be more susceptible to infection, and thus our analysis may overestimate seroincidence in this arm of the trial. This would have the effect of reducing any differences seen between study groups, and seroefficacy may therefore be underestimated in our analysis.
In conclusion, administration of Typbar TCV induces a robust Vi antibody response in children and adults that substantially reduces the seroincidence of infection by an estimated 85%, similar to the efficacy reported in a field trial of a different Vi-conjugate vaccine [5] . In the context of typhoid that occurs most often in children, a vaccine that can induce robust antibody responses in young infants and children and is effective in preventing infection is key to overcoming the current limitations of licensed typhoid vaccines.
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